Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454817 | 0.92 | — | — | |
| SCHEMBL10936422 | 0.89 | — | — | |
| SCHEMBL9551531 | 0.89 | — | — | |
| SCHEMBL11243568 | 0.89 | — | — | |
| Water SCHEMBL2235878 | 0.89 | — | — | |
| SCHEMBL5189838 | 0.89 | — | — | |
| Lactic Acid SCHEMBL28108148 | 0.83 | — | — | |
| Sulfuric Acid SCHEMBL1584319 | 0.82 | TP53 (0.35) | TP53 | |
| Lactic Acid SCHEMBL5355968 | 0.80 | — | — | |
| Lactic Acid SCHEMBL23781870 | 0.78 | TP53 (0.65) | TP53SLC7A5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105411870-B | Alkyl lactyllactate and preparation method thereof | 斯蒂潘公司 | 2018-12-25 | — | — | CN | disclosed |
| EP-2444060-B1 | Personal care composition | STEPAN CO (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-106974885-A | Acidic buffer gel for treating vaginitis | 佟丽 | 2017-07-25 | — | — | CN | disclosed |
| US-9233906-B2 | Purification of succinic acid from the fermentation broth containing ammonium succinate | Group Novasep SAS (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9174923-B2 | Alkyl lactyllactate solvent compositions | STEPAN COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9133092-B2 | Alkyl lactyllactates and processes of making the same | STEPAN COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140194646-A1 | Alkyl Lactyllactates and Processes of Making the Same | STEPAN COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-8642528-B2 | Alkyl lactyllactates and processes of making the same | STEPAN COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120289742-A1 | PURIFICATION OF SUCCINIC ACID FROM THE FERMENTATION BROTH CONTAINING AMMONIUM SUCCINATE | GROUPE NOVASEP SAS (FR) | 2012-11-15 | — | — | US | disclosed |
| EP-2041064-B1 | PROCESSES OF MAKING ALKYL LACTYLLACTATES | STEPAN CO (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2008006076-A2 | ALKYL LACTYLLACTATES AND PROCESSES OF MAKING THE SAME | STEPAN COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-1282494-C | Method for obtaining organic acid from organic acid ammonium salt, organic acid amide, or alkylamine-organic acid complex | STALEY MFG CO A E (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1385593-B1 | PROCESS FOR OBTAINING AN ORGANIC ACID FROM AN ORGANIC ACID AMMONIUM SALT, AN ORGANIC ACID AMIDE, OR AN ALKYLAMINE ORGANIC ACID COMPLEX | TATE & LYLE INGREDIENTS (US) | 2006-08-09 | — | — | EP | disclosed |
| US-6926810-B2 | Process for obtaining an organic acid from an organic acid ammonium salt, an organic acid amide, or an alkylamine organic acid complex | A. E. STALEY MANUFACTURING CO. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1385593-A4 | PROCESS FOR OBTAINING AN ORGANIC ACID FROM AN ORGANIC ACID AMMONIUM SALT, AN ORGANIC ACID AMIDE, OR AN ALKYLAMINE ORGANIC ACID COMPLEX | STALEY MFG CO A E (US) | 2004-08-11 | — | — | EP | disclosed |
| CN-1509197-A | Process for obtaining organic and from organic acid ammonium salt, an organic acid amide, or alkylamine organic acid complex | A��E��˹�������칫˾ | 2004-06-30 | — | — | CN | disclosed |
| EP-1385593-A1 | PROCESS FOR OBTAINING AN ORGANIC ACID FROM AN ORGANIC ACID AMMONIUM SALT, AN ORGANIC ACID AMIDE, OR AN ALKYLAMINE ORGANIC ACID COMPLEX | A.E. STALEY MANUFACTURING COMPANY (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030029711-A1 | Process for obtaining an organic acid from an organic acid ammonium salt, an organic acid amide, or an alkylamine organic acid complex | TATE & LYLE INGREDIENTS AMERICAS, INC. | 2003-02-13 | — | — | US | disclosed |
| WO-2002074403-A1 | PROCESS FOR OBTAINING AN ORGANIC ACID FROM AN ORGANIC ACID AMMONIUM SALT, AN ORGANIC ACID AMIDE, OR AN ALKYLAMINE ORGANIC ACID COMPLEX | A.E. STALEY MANUFACTURING CO. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6280985-B1 | Process for the separation and purification of lactic acid from a fermentation medium | ROQUETTE FRERES (FR) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194646-A1 | Alkyl Lactyllactates and Processes of Making the Same | LCT, LMAN1, ELOVL6 | TP53 2140/4885SLC7A5 1306/4885GABRR1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.